HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M800046-JLR200v1 M800046-JLR200v2 M800046-JLR200v3 49/8/1658    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Peterson, S. J. Articles by Abraham, N. G. PubMed PubMed Citation Articles by Peterson, S. J. Articles by Abraham, N. G. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 49, 1658-1669, August 2008
Copyright © 2008 by American Society for Biochemistry and Molecular Biology

L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice^*

Stephen J. Peterson^*, George Drummond, Dong Hyun Kim, Ming Li, Adam L. Kruger^*, Susumu Ikehara and Nader G. Abraham^1,*,

^* Departments of Medicine New York Medical College, Valhalla, NY 10595
Department of Pharmacology, New York Medical College, Valhalla, NY 10595
First Department of Pathology, Kansai Medical University, Moriguchi, Osaka, Japan

^* This work was supported by National Institutes of Health Grants DK-068134, HL-55601, and HL-34300.

Published, JLR Papers in Press, April 28, 2008.

¹To whom correspondence should be addressed. e-mail: nader_abraham{at}nymc.edu

We hypothesized that the apolipoprotein mimetic peptide L-4F, which induces arterial anti-oxidative enzymes and is vasoprotective in a rat model of diabetes, would ameliorate insulin resistance and diabetes in obese mice. L-4F (2 mg/kg/d) administered to ob/ob mice for 6 weeks limited weight gain without altering food intake, decreased visceral (P < 0.02) and subcutaneous (P < 0.045) fat content, decreased plasma IL-1β and IL-6 levels (P < 0.05) and increased insulin sensitivity, resulting in decreased glucose (P < 0.001) and insulin (P < 0.036) levels. In addition, L-4F treatment increased aortic and bone marrow heme oxygenase (HO) activity and decreased aortic and bone marrow superoxide production (P < 0.001). L-4F treatment increased serum adiponectin levels (P < 0.037) and decreased adipogenesis in mouse bone marrow (P < 0.039) and in cultures of human bone marrow-derived mesenchymal stem cells (P < 0.022). This was manifested by reduced adiposity, improved insulin sensitivity, improved glucose tolerance, increased plasma adiponectin levels, and reduced IL-1β and IL-6 levels in obese mice. This study highlights the existence of a temporal relationship between HO-1 and adiponectin that is positively affected by L-4F in the ob/ob mouse model of diabetes, resulting in the amelioration of the deleterious effects of diabetes.

Supplementary key words diabetes • apolipoprotein A-I mimetic peptides • heme oxygenase-1

Abbreviations: apoA-I, apolipoprotein A-I; HMW, high molecular weight; HO, heme oxygenase; LMW, low molecular weight; MSC, mesenchymal stem cell; ROS, reactive oxygen species

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?